Evogene Total Liabilities
Evogene total liabilities. Based on the latest financial reports, Evogene (EVGN) has total liabilities worth ILA8.83 Million ILA (≈ $23.68K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Evogene to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Evogene (2006–2024)
Total liabilities of Evogene from 2006 to 2024. This chart illustrates how Evogene's total liabilities have evolved over time, based on quarterly financial data. Explore Evogene long-term investment intensity to see how much of total assets are deployed in long-term investments.
Evogene Competitors by Total Liabilities
The table below lists competitors of Evogene ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Young & Co.'s Brewery P.L.C
LSE:YNGN
|
UK | GBX525.90 Million |
|
The Income & Growth VCT
LSE:IGV
|
UK | GBX347.63K |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
USA | $1.84 Million |
|
Seeing Machines Limited
LSE:SEE
|
UK | GBX88.34 Million |
|
Plaza Centers NV
WAR:PLZ
|
Poland | zł177.01 Million |
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
Indonesia | Rp1.28 Billion |
|
Catheter Precision Inc.
NYSE MKT:VTAK
|
USA | $9.21 Million |
|
Crown LNG Holdings Limited Warrants
NASDAQ:CGBSW
|
USA | $16.20 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Evogene's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Evogene balance sheet assets.
Liquidity & Leverage Metrics
Evogene Total Liabilities Ratios Explained
Evogene total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evogene's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evogene (2006–2024)
The table below shows the annual total liabilities of Evogene from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA25.03 Million ≈ $67.09K |
+11.64% |
| 2023-12-31 | ILA22.42 Million ≈ $60.10K |
+5.06% |
| 2022-12-31 | ILA21.34 Million ≈ $57.20K |
+65.60% |
| 2021-12-31 | ILA12.88 Million ≈ $34.54K |
-14.30% |
| 2020-12-31 | ILA15.03 Million ≈ $40.30K |
+34.86% |
| 2019-12-31 | ILA11.15 Million ≈ $29.88K |
+32.89% |
| 2018-12-31 | ILA8.39 Million ≈ $22.49K |
+1.99% |
| 2017-12-31 | ILA8.22 Million ≈ $22.05K |
-5.44% |
| 2016-12-31 | ILA8.70 Million ≈ $23.32K |
-1.65% |
| 2015-12-31 | ILA8.84 Million ≈ $23.71K |
-23.13% |
| 2014-12-31 | ILA11.50 Million ≈ $30.84K |
-8.44% |
| 2013-12-31 | ILA12.56 Million ≈ $33.68K |
-24.30% |
| 2012-12-31 | ILA16.60 Million ≈ $44.49K |
-16.19% |
| 2011-12-31 | ILA19.80 Million ≈ $53.09K |
-24.25% |
| 2010-12-31 | ILA26.14 Million ≈ $70.08K |
+11.04% |
| 2009-12-31 | ILA23.54 Million ≈ $63.12K |
-3.27% |
| 2008-12-31 | ILA24.34 Million ≈ $65.25K |
+390.59% |
| 2007-12-31 | ILA4.96 Million ≈ $13.30K |
+56.89% |
| 2006-12-31 | ILA3.16 Million ≈ $8.48K |
-- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more